Skip to main navigation
Skip Navigation
Landos Biopharma

    • - Landos - Corp Menu

  • About Us
    • Our Company
      • Management Team
      • Board of Directors
      • Clinical Advisory Board
    • Contact Us
  • Product Candidates
    • NX-13
    • Preclinical Candidates
    • Clinical Trials
  • Science
    • LANCE Precision Medicine Platform
    • Immunometabolic Pathways
    • Publications
  • Investors/Media
    • Investor/Media Home
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investors/Media FAQs
  • Careers
    • Why Landos?
    • Open Positions
Identifying novel pathways at the interface of immunity and metabolism

SEC Filing Details

Document Details

Form
EFFECT
Filing Date
Feb 3, 2021
Document Date
Feb 3, 2021
Form Description
EFFECT
Filing Group
Other
Company
Landos Biopharma
Issuer
Landos Biopharma, Inc.

Filing Formats

View HTML
Download PDF 72.7 KB
Download DOC
Download XLS

Investors/Media

Investor Relations

  • Investor/Media Home
  • Press Releases
  • Events & Presentations
  • Analyst Coverage
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investors/Media FAQs

- Landos - Investor Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
Landos Biopharma, Inc.
PO Box 11239
Blacksburg, VA 24062
info@landosbiopharma.com
(540) 218-2232

- Landos - Footer Menu

  • Site Map
  • Terms of Use
  • Privacy Policy

©2023 Landos Biopharma All Rights Reserved.